Let's Go Lentiviral !
Welcome to the Lentivirus Galaxy ;
Check out our various resources to learn all the secrets of lentiviral vectors.
Explore our downloadable documents, news, articles and FAQ.
The following categories :
- Posters & Press release
- Application notes & Technical notes
- End User Rights & other
Leni Hector,
Mascot for Flash Therapeutics since 2023
Posters
- POSTER ESGCT FLASHRNA IN VIVO
-
A game-changing RNA delivery platform combining high cell entry and multiple RNA trasnfer for next generation therapy : LentiFlash® (ESGCT 2023)
-
Lentivirus Manufacturing : successful & reproducible continuum process from research batches to clinical application (ISCT 2023)
-
Next Generation Therapy : RNA delivery by LentiFlash for an efficient CRISPR/Cas9-mediated gene knockout in Human iPS (EBMT 2023)
-
NK cells engineering using advanced Lentiviral Vectors quality and design (EBMT 2023)
-
GMP platform for lentiviral vector production with 9000 batches produced (Advanced Therapies 2023)
-
Gene editing on primary & stem cells using LentiFlash RNA delivery approach (ASGCT 2022)
-
Efficient & safe delivery of multiple mRNA using non-integrative bacteriophage-chimeric retrovirus-like particles for in vivo application (ASGCT 2022)
-
All-in-one delivery using lentiflash (ESGCT 2019)
-
Primary cells and in vivo immunomodulation using LentiFlash®, a chimeric RNA delivery technology designed for clinical applications
-
All-in-one Delivery Using LentiFlash® technology, a MS2-chimeric RNA Delivery Tool Designed for Clinical Applications (ASGCT 2019)
-
All-in-one delivery of gene-editing system into primary cells and in vivo using LentiFlash®, an MS2-chimeric viral RNA delivery tool designed for clinical applications (ESGCT 2018)
-
How to monitor a specific cell state ?
-
How to label specific cells or tissues in vitro and in vivo ?
-
How to follow the cell differentiation process ?
-
Large scale production of lentiviral tools
-
Need to precisely control gene expression in your cells ?
-
Lentiviral vectors with tissue or cell specific promoters
-
Predictive immunotherapy models (Poster AACR 2015)
-
Lentiviral Vectors for in Vitro and in Vivo target Validation (Poster SFTCG 2009)
-
Generation of primary cells using lentiviral vectors (Poster SBS 2011)
Application notes
-
Lentiviral vectors with tissue or cell-specific promoters
-
Overview of tissue specific promoters available in pre-made products format
-
Differences between lentiviral vectors and LentiFlash particles
-
Large scale production of lentiviral tools
-
Lentiviral vectors with TET-on 3G system
-
Premade lentiviral vectors to label specific cells or tissues
-
Premade lentiviral vectors to follow the cell differentiation pathway
-
Custom and premade lentiviral vectors with cell state specific promoters
-
Enhance your production efficiency with optimal plasmid ratio
-
Custom and premade lentiviral vectors with cell state specific promoters
Press release
- PR (EN) - Flash BioSolutions appoints Anne DEFLISQUE Business & Marketing Director to boost g rowth
- PR (EN) - Introducing Flash BioSolutions : Spearheading advancements in Biopharmaceutical CDMO sector
- PR (EN) - Flash BioSolutions obtains Pharmaceutical Establishment status, opening up new avenues for its FlashRNA® technology
- CP (FR) - Flash BioSolutions obtient le statut d'établissement pharmaceutique, ouvrant de nouvelles voies pour sa technologie FlashRNA®
- Press release (EN) - Collaboration between CEA & Flash Therapeutics for the development of cutaneous cell therapy
- CP (FR) - Coopération entre le CEA et Flash Therapeutics dans le domaine de la thérapie cellulaire cutanée
- Press release (EN) - Flash Therapeutics appoints Jérôme Bédier as President
- CP (FR) - Flash Therapeutics nomme Jérôme Bédier Président
- Communiqué - Flash Therapeutics et la stratégie vaccinale
- Flash Therapeutics presentation
- Press release - Magenta - EN
Technical notes
-
E-BOOK 2023 - CDMO LENTIVIRAL VECTOR - R&D OFFER
-
What is LentiFlash?
-
Lentiviral vectors or LentiFlash particles ?
-
Physical properties of fluorescent proteins available with lentiviral particles
-
GMP lentiviral particle manufacturing
End User Rights
- End User Rights custom LentiFlash
- End User Rights premade LentiFlash with fluorescent protein
- End User Rights LentiFlash plasmids
- End User Rights custom lentiviral vectors
- End User Rights custom lentiviral vectors with fluorescent protein
- End User Rights premade lentiviral vectors for gene editing
- End User Rights premade LentiFlash for gene editing
- End User Rights premade LentiFlash with Luc
- End User Rights premade lentiviral vectors with Luc
- End User Rights premade lentiviral vectors NegControl
- End User Rights premade lentiviral vectors with fluorescent protein under specific promoter
- End User RightsEnd User Rights premade lentiviral vectors with Luc under specific promoter
- End User Rights custom lentiviral vectors with TetON3G
- End User Rights premade lentiviral vectors with fluorescent protein (for products distributed by Vectalys)
Other
- 01 - Conditions générales de vente - Flash Therapeutics
- 01 - General terms and conditions of sale - Flash Therapeutics
- 02 - Flash Therapeutics Quality Policy
- 02 - Vectalys Quality Policy - transport
- 03 - Material Safety Data Sheet Lentiviral vectors (FR)
- 03 - Material Safety Data Sheet Lentiviral vectors (EN)
- 04 - List of our own publications
- 05 - Patent list that quote Vectalys
- 06 - Why customers prefer Flash Therapeutics lentiviral vectors ?
-
06 - Why customers prefer Vectalys lentiviral vectors ?
-
07 - Non-exhaustive list of cells transduced with almost 100% efficiency